Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Tobacco Use Cessation Devices 2zileuton 1olaparib 1Vitamin B 12 1Varenicline 1Radiotherapy 1Patient Navigation 1Nicotine Replacement Therapy 1Folic Acid 1Erlotinib Hydrochloride 1Cycloserine 1Cetuximab 1Celecoxib 1Budesonide 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoking × Erlotinib Hydrochloride × Clear all
NCT00606502 2021-03-05

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
201 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking

Data powered by HemOnc (CC BY 4.0) Colophon âš¡